FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280644653> ?p ?o ?g. }

• W4280644653 abstract "Abstract Ivermectin is a safe and effective drug in humans and has been approved for use in numerous parasitic infections for over 50 years. In addition, many studies have already shown its antiviral activity. Ivermectin is generally well tolerated, with no indication of central nervous system-associated toxicity at doses up to 10 times the highest FDA-approved dose of 200 µg/kg. The in vitro results of ivermectin for reducing SARS-CoV-2 viral load are promising and show that Ivermectin kills SARS-CoV-2 within 48 hours. A hypothesized mechanism of action for this drug is a likely inhibition of IMPα/β1-mediated nuclear import of viral proteins as demonstrated for other RNA viruses. However, controlled and randomized studies are needed to prove its effectiveness in COVID-19 in humans. In a single in vivo study with published results, patients confirmed to be infected with SARS-CoV-2 received at least one dose of ivermectin at any time during hospitalization. The use of ivermectin was associated with lower mortality during treatment with COVID-19, especially in patients who required increased inspired oxygen or ventilatory support. Additionally, 81 studies with the clinical use of ivermectin in humans are being carried out worldwide according to ClinicalTrials.gov. However, none of these data has been published so far. However, private and public entities in Brazil have been adopting this drug in their protocols as prophylaxis and in the initial phase of the disease. In addition, ivermectin has been used in mass treatment to prevent onchocerciasis and lymphatic filariasis in sub-Saharan Africa for many years. Surprisingly, this region has the lowest proportional mortality rate among the continents, despite the increasing numbers of infected people released by the World Health Organization." @default.
• W4280644653 created "2022-05-22" @default.
• W4280644653 creator A5014999861 @default.
• W4280644653 creator A5019781145 @default.
• W4280644653 creator A5049173448 @default.
• W4280644653 creator A5080706378 @default.
• W4280644653 date "2024-01-01" @default.
• W4280644653 modified "2023-10-17" @default.
• W4280644653 title "Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols" @default.
• W4280644653 cites W184796188 @default.
• W4280644653 cites W1986276373 @default.
• W4280644653 cites W2036455421 @default.
• W4280644653 cites W2072780759 @default.
• W4280644653 cites W2094563618 @default.
• W4280644653 cites W2104930292 @default.
• W4280644653 cites W2587955855 @default.
• W4280644653 cites W2606413115 @default.
• W4280644653 cites W2928276993 @default.
• W4280644653 cites W2995527246 @default.
• W4280644653 cites W2996025567 @default.
• W4280644653 cites W3001552927 @default.
• W4280644653 cites W3005879843 @default.
• W4280644653 cites W3014962324 @default.
• W4280644653 cites W3016232405 @default.
• W4280644653 cites W3033863786 @default.
• W4280644653 cites W3035026987 @default.
• W4280644653 cites W3035706118 @default.
• W4280644653 cites W3091860795 @default.
• W4280644653 cites W3111068209 @default.
• W4280644653 cites W3168908540 @default.
• W4280644653 cites W3170319714 @default.
• W4280644653 cites W4253143966 @default.
• W4280644653 doi "https://doi.org/10.1590/1519-6984.258325" @default.
• W4280644653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35584459" @default.
• W4280644653 hasPublicationYear "2024" @default.
• W4280644653 type Work @default.
• W4280644653 citedByCount "1" @default.
• W4280644653 crossrefType "journal-article" @default.
• W4280644653 hasAuthorship W4280644653A5014999861 @default.
• W4280644653 hasAuthorship W4280644653A5019781145 @default.
• W4280644653 hasAuthorship W4280644653A5049173448 @default.
• W4280644653 hasAuthorship W4280644653A5080706378 @default.
• W4280644653 hasConcept C203014093 @default.
• W4280644653 hasConcept C2777499811 @default.
• W4280644653 hasConcept C2780035454 @default.
• W4280644653 hasConcept C2780727990 @default.
• W4280644653 hasConcept C2911037157 @default.
• W4280644653 hasConcept C535046627 @default.
• W4280644653 hasConcept C60644358 @default.
• W4280644653 hasConcept C86803240 @default.
• W4280644653 hasConcept C90856448 @default.
• W4280644653 hasConcept C98274493 @default.
• W4280644653 hasConceptScore W4280644653C203014093 @default.
• W4280644653 hasConceptScore W4280644653C2777499811 @default.
• W4280644653 hasConceptScore W4280644653C2780035454 @default.
• W4280644653 hasConceptScore W4280644653C2780727990 @default.
• W4280644653 hasConceptScore W4280644653C2911037157 @default.
• W4280644653 hasConceptScore W4280644653C535046627 @default.
• W4280644653 hasConceptScore W4280644653C60644358 @default.
• W4280644653 hasConceptScore W4280644653C86803240 @default.
• W4280644653 hasConceptScore W4280644653C90856448 @default.
• W4280644653 hasConceptScore W4280644653C98274493 @default.
• W4280644653 hasLocation W42806446531 @default.
• W4280644653 hasLocation W42806446532 @default.
• W4280644653 hasLocation W42806446533 @default.
• W4280644653 hasOpenAccess W4280644653 @default.
• W4280644653 hasPrimaryLocation W42806446531 @default.
• W4280644653 hasRelatedWork W177093907 @default.
• W4280644653 hasRelatedWork W1968271983 @default.
• W4280644653 hasRelatedWork W1969969853 @default.
• W4280644653 hasRelatedWork W2009292171 @default.
• W4280644653 hasRelatedWork W2132773307 @default.
• W4280644653 hasRelatedWork W2167582113 @default.
• W4280644653 hasRelatedWork W2189021328 @default.
• W4280644653 hasRelatedWork W2405054821 @default.
• W4280644653 hasRelatedWork W2419600336 @default.
• W4280644653 hasRelatedWork W2580614359 @default.
• W4280644653 hasVolume "84" @default.
• W4280644653 isParatext "false" @default.
• W4280644653 isRetracted "false" @default.
• W4280644653 workType "article" @default.